IDEXX Laboratories Exec Says ~1/4th Of Cancerdx Orders In Q3 Came From Non-Primary Reference Lab Customers; Covet Rev Run Rate Is About $20M Annualized, Growing At Strong Double-Digit Rates

Benzinga
Open on Benzinga